JP2017513938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513938A5 JP2017513938A5 JP2017504294A JP2017504294A JP2017513938A5 JP 2017513938 A5 JP2017513938 A5 JP 2017513938A5 JP 2017504294 A JP2017504294 A JP 2017504294A JP 2017504294 A JP2017504294 A JP 2017504294A JP 2017513938 A5 JP2017513938 A5 JP 2017513938A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- mupirocin
- molar ratio
- range
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims 41
- 150000002632 lipids Chemical class 0.000 claims 23
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 16
- 229960003128 mupirocin Drugs 0.000 claims 16
- 229930187697 mupirocin Natural products 0.000 claims 16
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 16
- 150000001450 anions Chemical class 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 239000012528 membrane Substances 0.000 claims 7
- 229920000858 Cyclodextrin Polymers 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 cyclodextrin compound Chemical class 0.000 claims 5
- 235000012000 cholesterol Nutrition 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 238000007910 systemic administration Methods 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977731P | 2014-04-10 | 2014-04-10 | |
| US61/977,731 | 2014-04-10 | ||
| PCT/IL2015/050376 WO2015155773A1 (en) | 2014-04-10 | 2015-04-08 | Liposomal mupirocin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513938A JP2017513938A (ja) | 2017-06-01 |
| JP2017513938A5 true JP2017513938A5 (cg-RX-API-DMAC7.html) | 2018-04-26 |
| JP6676035B2 JP6676035B2 (ja) | 2020-04-08 |
Family
ID=53177332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504294A Active JP6676035B2 (ja) | 2014-04-10 | 2015-04-08 | リポソームムピロシン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10004688B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3142642B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6676035B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106659795B (cg-RX-API-DMAC7.html) |
| DK (1) | DK3142642T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015155773A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI754659B (zh) * | 2016-08-08 | 2022-02-11 | 台灣微脂體股份有限公司 | 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組 |
| EP3520819A1 (en) | 2018-01-31 | 2019-08-07 | Universität Basel | Shear stress sensitive liposomes |
| US20220347096A1 (en) * | 2019-10-03 | 2022-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Liposomal cannabinoids and uses thereof |
| EP4125809A1 (en) * | 2020-03-25 | 2023-02-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Liposomal formulations comprising at1 receptor blockers and uses thereof |
| CN116270433B (zh) * | 2023-03-14 | 2023-09-01 | 郑州大学第一附属医院 | 一种莫匹罗星软膏、制备方法及用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
| DE69632859T2 (de) * | 1995-04-18 | 2005-07-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung |
| US20060110441A1 (en) * | 2004-10-28 | 2006-05-25 | Harry Wong | Lyophilized liposome formulations and method |
| WO2007005754A2 (en) | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
| WO2007044745A1 (en) * | 2005-10-11 | 2007-04-19 | Biosynexus Incorporated | Lantibiotic and mupirocin compositions for treating bacterial infections |
| US20090196918A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions |
| CN102048693B (zh) * | 2009-10-26 | 2013-08-21 | 石药集团中奇制药技术(石家庄)有限公司 | 具有苯磺酸衍生物内水相的脂质体 |
| US20130337051A1 (en) * | 2011-03-01 | 2013-12-19 | To-Bbb Holding B.V. | Advanced active liposomal loading of poorly water-soluble substances |
-
2015
- 2015-04-08 US US15/303,131 patent/US10004688B2/en active Active
- 2015-04-08 CN CN201580019117.7A patent/CN106659795B/zh active Active
- 2015-04-08 JP JP2017504294A patent/JP6676035B2/ja active Active
- 2015-04-08 DK DK15722359.5T patent/DK3142642T3/en active
- 2015-04-08 WO PCT/IL2015/050376 patent/WO2015155773A1/en not_active Ceased
- 2015-04-08 EP EP15722359.5A patent/EP3142642B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alavi et al. | Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery | |
| JP2017513938A5 (cg-RX-API-DMAC7.html) | ||
| Gharib et al. | Liposomes incorporating cyclodextrin–drug inclusion complexes: Current state of knowledge | |
| US9968583B2 (en) | Method of manufacture of liposome composition | |
| EP4420679A3 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MX2024001218A (es) | Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia. | |
| JP2019501198A5 (cg-RX-API-DMAC7.html) | ||
| JP2008512446A5 (cg-RX-API-DMAC7.html) | ||
| EA201890367A1 (ru) | Композиции и способы для лиофильных форм наночастиц | |
| Zhai et al. | Dermal nanocrystals from medium soluble actives–physical stability and stability affecting parameters | |
| Alihosseini et al. | Freeze-drying of ampicillin solid lipid nanoparticles using mannitol as cryoprotectant | |
| JP2016529284A5 (cg-RX-API-DMAC7.html) | ||
| WO2009108828A3 (en) | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof | |
| JP2018521083A5 (cg-RX-API-DMAC7.html) | ||
| US20190328665A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
| JP6893245B2 (ja) | 脂質ナノ粒子用膜材料組成物 | |
| JP6705933B2 (ja) | リポソーム組成物およびその製造方法 | |
| WO2016040887A3 (en) | Multilamellar lipid vesicle compositions and methods of use | |
| TW200726485A (en) | Liposomal delivery vehicle for hydrophobic drugs | |
| RU2020137384A (ru) | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина | |
| WO2015166987A1 (ja) | リポソーム組成物及びその製造方法 | |
| JP6263609B2 (ja) | リポソーム組成物及びその製造方法 | |
| Swarnakar et al. | Effect of co-administration of CoQ10-loaded nanoparticles on the efficacy and cardiotoxicity of doxorubicin-loaded nanoparticles | |
| BR112018068000A2 (pt) | composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2) | |
| EP3821911A4 (en) | NUCLEIC ACID NANOPARTICLES, PHARMACEUTICAL COMPOSITION COMPRISING THEM, MEDICATION COMPRISING DOXORUBICIN, AND METHOD FOR PREPARING THEM |